Polynucleotides encoding SARS-COV-2 antigens and use thereof in the medical field as vaccines

A polynucleotide encoding an amino acid sequence, an expression vector comprising said polynucleotide, or a pharmaceutical composition comprising said polynucleotide or expression vector in combination with one or more excipients and/or adjuvants, wherein the polynucleotide comprises or consists of a sequence selected from:

• SEQ ID NO:1 fused to the C-terminal of the tissue plasminogen activator (TPA) secretion leader sequence, said sequence SEQ ID NO:1 encoding an amino acid sequence consisting of the receptor binding domain (RBD) domain of the S1 subunit of the spike protein of the SARS-CoV-2 virus or of variants thereof;
• a sequence having a percent identity greater than or equal to 80% compared to sequence SEQ ID NO:1, selected from SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:21, alone or fused to the C-terminal of the tissue plasminogen activator (TPA) secretion leader sequence;
• SEQ ID NO:2, which encodes an amino acid sequence consisting of the N-terminal domain (NTD) and RBD domains of the S1 subunit of the spike protein of the SARS-CoV-2 virus;
• SEQ ID NO:3, which encodes an amino acid sequence consisting of the NTD, RBD, C-terminal domain 2 (CTD2) and C-terminal domain 3 (CTD3) domains of the S1 subunit of the spike protein of the SARS-CoV-2 virus;
• SEQ ID NO:5, which encodes an amino acid sequence consisting of the spike protein of the SARS-CoV-2 virus;
• and
• SEQ ID NO:4, which encodes an amino acid sequence consisting of the RBD domain of the S1 subunit of the spike protein of the SARS-CoV-2 virus, said domain being fused at the N-terminal end to the IgK leader sequence and at the C-terminal end to the Fc immunomodulating sequence.